Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
ApexOnco Front Page
Recent articles
The players are vying in the CD19 x CD20 Car-T arena.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
The move follows promising but early data presented at ASCO.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
First-in-human trial starts include 3SBio's SSGJ-708 and in vivo Car-Ts from Legend and Starna.
